Client investigational drug represents a first-in-class therapy poised to fundamental change the practice of medicine across multiple therapeutic areas
Client submitted phase 2 clinical trial data as an abstract to the most prestigious medical conference for the therapeutic area
Challenge
The medical congress scientific committee determined that the abstract warranted acceptance for presentation but as a poster only instead of a potential oral podium presentation
Resolution
Xelay Acumen created and leveraged personal relationships to gain a re-evaluation of the abstract, provide context for the scientific committee to consider, and rewrote the abstract to appropriately and clearly communicate the importance of the data to the medical and scientific community
The decision on the abstract was revised to be the highlight of the late-breaking clinical trials session, the most prestigious venue of the conference